EGFR and non-small cell lung carcinoma: Metapristone treatment intervened the EMT-related signaling pathway to realize breast cancer metastasis chemoprevention [14], suppressed non-small cell lung cancer (NSCLC) proliferation and metastasis by targeting RAS/RAF/MER/MAPK and EGFR-mediated PI3K/Akt pathways [15, 16].